Dalcetrapib, a CETP inhibitor for treating acute coronary syndrome, has its efficacy potentially influenced by genetic variations in the ADCY9 gene. These gene variations can affect the pharmacodynamics of dalcetrapib, particularly in how it alters lipid metabolism or plaque stability in the arteries, thus impacting therapeutic responsiveness.